CGEM FY 2021 Earnings — Cullinan Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

CGEMCullinan Therapeutics, Inc.

$894M

FY 2021 Earnings

Healthcare Medical - Pharmaceuticals

Income Statement

Revenue

$19M

Gross Profit

$19M100.0% margin

Operating Income

-$68M-358.7% margin

Net Income

-$66M-346.1% margin

EPS (Diluted)

$-1.48

Cash Flow

Operating Cash Flow

-$43M

Free Cash Flow

-$44M

Stock-Based Comp.

$24M

Balance Sheet

Total Assets

$437M

Total Liabilities

$12M

Stockholders' Equity

$425M

Cash & Equivalents

$60M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$19M	$0	—
Gross Profit	$19M	-$62,000	+30653.2%
Operating Income	-$68M	-$60M	-12.6%
Net Income	-$66M	-$52M	-26.6%